279 related articles for article (PubMed ID: 17562985)
1. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy.
Finger PT; Chin K
Arch Ophthalmol; 2007 Jun; 125(6):751-6. PubMed ID: 17562985
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy.
Finger PT
Am J Ophthalmol; 2007 Feb; 143(2):335-8. PubMed ID: 17258524
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study.
Finger PT; Chin KJ; Semenova EA
Eur J Ophthalmol; 2016; 26(1):60-6. PubMed ID: 26391167
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
Mason JO; Albert MA; Persaud TO; Vail RS
Retina; 2007 Sep; 27(7):903-7. PubMed ID: 17891015
[TBL] [Abstract][Full Text] [Related]
5. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
Gupta A; Muecke JS
Retina; 2008; 28(7):964-8. PubMed ID: 18698298
[TBL] [Abstract][Full Text] [Related]
6. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.
Finger PT; Chin KJ
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):789-98. PubMed ID: 21277107
[TBL] [Abstract][Full Text] [Related]
7. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin).
Finger PT
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):974-7. PubMed ID: 18313522
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.
Finger PT; Mukkamala SK
Eur J Ophthalmol; 2011; 21(4):446-51. PubMed ID: 21218391
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma.
Ziemssen F; Voelker M; Altpeter E; Bartz-Schmidt KU; Gelisken F
Acta Ophthalmol Scand; 2007 Aug; 85(5):579-80. PubMed ID: 17324216
[No Abstract] [Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.
Shah SU; Shields CL; Bianciotto CG; Iturralde J; Al-Dahmash SA; Say EAT; Badal J; Mashayekhi A; Shields JA
Ophthalmology; 2014 Jan; 121(1):269-275. PubMed ID: 24139123
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
15. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
Kovach JL; Rosenfeld PJ
Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
[TBL] [Abstract][Full Text] [Related]
17. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AT 2-MONTH INTERVALS REDUCES FOVEAL AVASCULAR ZONE ENLARGEMENT AND VISION LOSS IN RADIATION MACULOPATHY: A Pilot Study.
Daruich A; Matet A; Schalenbourg A; Zografos L
Retina; 2019 Aug; 39(8):1519-1526. PubMed ID: 29746413
[TBL] [Abstract][Full Text] [Related]
18. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
Charbel Issa P; Holz FG; Scholl HP
Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]